# Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

> **NCT00141531** · PHASE2 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 53 (actual)

## Conditions studied

- Bladder Neoplasms

## Interventions

- **DRUG:** Apaziquone

## Key facts

- **NCT ID:** NCT00141531
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2012-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141531, "Phase II Trial of EOquin in High-risk Superficial Bladder Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00141531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*